Protagonist Therapeutics (PTGX) Earning Somewhat Favorable Press Coverage, Study Finds

News coverage about Protagonist Therapeutics (NASDAQ:PTGX) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Protagonist Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.8075735761446 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Protagonist Therapeutics (NASDAQ:PTGX) opened at $17.57 on Wednesday. Protagonist Therapeutics has a twelve month low of $8.00 and a twelve month high of $23.65.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.40. The company had revenue of $8.78 million for the quarter. equities analysts expect that Protagonist Therapeutics will post -3.66 EPS for the current fiscal year.

PTGX has been the topic of a number of analyst reports. ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. BMO Capital Markets boosted their price target on Protagonist Therapeutics from $40.00 to $43.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Friday, August 18th. Finally, BidaskClub downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $32.67.

In related news, insider David Y. Liu sold 7,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $16.97, for a total transaction of $118,790.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Richard S. Shames sold 2,017 shares of the company’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $19.00, for a total transaction of $38,323.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 9,892 shares of company stock valued at $174,613. 15.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply